RxDoctor Payments DataLook up a doctor →

Michael Asbach

Physician Assistant · Amherst, NYNPI 1699030411

Payments from drug & device makers

$961,873in general payments, 2019–2025

Across 2,773 payments — averaging $346.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$273K
  • Neurocrine Biosciences, Inc.$250K
  • Axsome Therapeutics, Inc.$126K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$99K
  • E.r. Squibb & Sons, L.L.C.$79K
  • Teva Pharmaceuticals USA, Inc.$37K
  • plus $98K from 49 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)520$272,773
Neurocrine Biosciences, Inc.385$249,785
Axsome Therapeutics, Inc.214$125,603
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)295$99,461
E.r. Squibb & Sons, L.L.C.115$78,743
Teva Pharmaceuticals USA, Inc.188$37,497
AbbVie(2 entities)153$35,792
Otsuka America Pharmaceutical, Inc.207$28,364
Avanir Pharmaceuticals, Inc.57$9,881
Janssen Scientific Affairs, LLC15$8,366
Biogen10$3,027
Sage Therapeutics, LLC2$2,290
Alkermes, Inc.90$1,762
Lundbeck LLC130$1,685
Vanda Pharmaceuticals Inc.67$1,376
Takeda Pharmaceuticals U.S.A., Inc.86$914
Sunovion Pharmaceuticals Inc.46$881
Jazz Pharmaceuticals Inc.26$519
Idorsia Pharmaceuticals US Inc29$431
Supernus Pharmaceuticals, Inc.14$335
Acadia Pharmaceuticals Inc15$279
Indivior Inc.14$246
Eisai Inc.13$243
Livanova USA, Inc.7$166
Corium, LLC9$164
Arbor Pharmaceuticals, Inc.8$153
Biohaven Pharmaceuticals, Inc.4$144
Orexo US, Inc.6$95
Catalyst Pharmaceuticals, Inc.4$95
Bausch Health US, LLC5$81
Azurity Pharmaceuticals, Inc.3$73
UCB, Inc.4$68
Merck3$60
Merz Pharmaceuticals, LLC3$60
Boehringer Ingelheim2$39
Abbott2$37
Noven Therapeutics, LLC2$37
Harmony Biosciences LLC1$35
Otsuka Pharmaceutical Development & Commercialization, Inc.1$31
Biohaven Pharmaceutical Holding Company Ltd.2$28
Currax Pharmaceuticals LLC2$25
Lilly USA, LLC1$24
Invivyd Inc1$23
Upsher-smith Laboratories LLC1$19
SK Life Science, Inc.1$18
Amgen1$18
Alnylam Pharmaceuticals Inc.1$17
Alfasigma USA, Inc.1$16
Bristol Myers Squibb1$16
Fennec Pharmaceuticals, Inc.1$16
Luye Pharma (USA) Ltd.1$14
Banner Life Sciences, LLC1$14
Amneal Pharmaceuticals LLC1$13
Almatica Pharma LLC1$13
Collegium Pharmaceutical, Inc.1$13

How this compares

$961,873 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$40,805
Medicare patients
131
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other physician assistant in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →